1. argenx SE (NASDAQ:ARGX)
argenx SE takes the top spot in this biotech watchlist because it represents one of the strongest commercial immunology stories in the market. This is not a small biotech hoping for its first big approval. It is already generating billion-dollar quarterly product sales from VYVGART, while still expanding into additional autoimmune diseases. For investors watching the best biotech stocks to buy now, argenx stands out because it combines growth, profitability, global adoption, label expansion, and a deep pipeline in severe autoimmune disease.
The May 2026 watchlist described argenx as a biotechnology company developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China. Its lead product candidate, efgartigimod, is being developed for multiple conditions, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, Sjögren’s disease, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. That is a broad autoimmune pipeline, and that breadth is one reason investors continue to watch the stock closely.
argenx reported $1.3 billion in global product net sales for the first quarter of 2026, representing 63% year-over-year growth. Total operating income was $1.3 billion, compared with $0.8 billion in the same period of 2025. Profit for the period reached $366 million, compared with $169 million a year earlier, representing 116% growth. Basic profit per share was $5.90, compared with $2.78 in the first quarter of 2025, while diluted profit per share was $5.52, compared with $2.58.
CEO Karen Massey said, “argenx continues to deliver meaningful impact for patients,” noting that the company achieved its 17th consecutive quarter of VYVGART growth. She also said VYVGART has the potential to become the first and only approved therapy across MG, pending FDA decisions on label expansions into seronegative and ocular populations. This quote is especially important because it explains the market’s excitement: the company is not only growing the current VYVGART franchise, but also trying to widen its label and reach more patients.
The company’s Vision 2030 is also ambitious. argenx wants to treat 50,000 patients globally, secure 10 labeled indications, and progress five pipeline candidates into Phase 3 development by 2030. That gives investors a clear long-term roadmap. In biotech, roadmaps matter because the market wants to know whether a company’s current success can become a larger platform. argenx is trying to show that VYVGART is not just a single-product win, but the foundation of a broader immunology franchise.
The catalyst calendar is also important. The company highlighted a May 10, 2026 PDUFA target action date for anti-AChR antibody negative generalized myasthenia gravis, planned label expansion into ocular myasthenia gravis, expected topline results from the ALKIVIA study in myositis in the third quarter of 2026, expected primary ITP data in the first half of 2027, and a planned Graves’ disease registrational study in 2026. It also expects a VYVGART SC autoinjector launch in 2027 for all approved indications.
For investors searching for top biotech stocks to watch now, autoimmune disease stocks, immunology biotech stocks, high-growth biotech stocks, and best biotech stocks for May 2026, argenx may be one of the most interesting names because it has both current sales momentum and future expansion potential. The risk is valuation and execution. When a biotech company becomes this successful, the market expects continuous growth, clean regulatory progress, and strong pipeline updates. Any disappointment can pressure the stock quickly. But based on available data, argenx currently has one of the strongest combinations of commercial growth, pipeline optionality, profitability, and management confidence in the biotech sector.
READ ALSO: Top 10 Biotech Stocks That Could Explode in 2026 and Top 10 Small-Cap FDA Catalyst Biotech Stocks.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
